BCM
ANGO icon

BlueCrest Capital Management’s AngioDynamics ANGO Stock Holding History

BlueCrest Capital Management’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,107
Closed -$175K – 901
2017
Q1 		$175K Buy
+10,107
New +$169K 0.01% 648

Other funds holding ANGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sentinel Asset Management Montpelier, Vermont $868K AUM 45.44% 1-Year Est. Return

BlueCrest Capital Management's ANGO Position: Q2 2017 in Review

BlueCrest Capital Management sold out of AngioDynamics (ANGO) in Q2 2017, closing a stake of 10,107 shares — an estimated $175K sold.

BlueCrest Capital Management first reported a position in ANGO in Q1 2017 and held it in 1 quarter. The position peaked at $175K in Q1 2017. 167 funds tracked by Wall St. Rank hold ANGO as of Q2 2017.

  • BlueCrest Capital Management reported no remaining AngioDynamics position as of Q2 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 10,107 AngioDynamics shares in Q2 2017, an estimated $175K.
  • BlueCrest Capital Management first reported a position in AngioDynamics in Q1 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's AngioDynamics position peaked at $175K in Q1 2017.
  • 167 funds tracked by Wall St. Rank held AngioDynamics as of Q2 2017.

Based on BlueCrest Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.